Adrian Sacher, MD, MMSc, FRCPC

Dr. Sacher is a staff medical oncologist in the thoracic and genitourinary tumor sites at the Princess Margaret Cancer Centre and an Assistant Professor of medicine at the University of Toronto. He has previously worked at the Herbert Irving Comprehensive Cancer Center at Columbia University & New York-Presbyterian Hospital where he served as an Assistant Professor of medicine and attending medical oncologist specializing in thoracic oncology and phase I drug development. Dr. Sacher completed his medical degree at the University of Toronto and residency at the Toronto General Hospital and Princess Margaret Cancer Center. He has previously completed a fellowship in thoracic oncology at the Dana-Farber Cancer Institute and holds a Master’s degree in clinical trial design, genomics and drug development from Harvard Medical School.

Dr. Sacher’s research focuses on novel immunotherapeutics including immune checkpoint inhibitors, immune agonists, vaccines and epigenetic therapy. He is primarily interested in understanding the mechanisms of primary and acquired resistance to immunotherapy and developing tissue and blood based biomarkers as well as humanized animal models to better understand the biology of anti-tumor immune responses. He has significant previous translational research experience in both tissue genomics and the development of blood-based biomarkers including plasma genotyping. He has been awarded an American Society of Clinical Oncology (ASCO) Career Development Award (CDA) for the study of mechanisms of resistance to immunotherapy in early stage lung cancer. He has also previously been awarded an International Association for the Study of Lung Cancer (IASLC) Fellowship, Canadian Institutes for Health Research (CIHR) Fellowship and a Canadian Association of Medical Oncologists (CAMO) Fellowship for his research.

Cancer Med. 2019 Oct 24;:
Jiang SX, Walton RN, Hueniken K, Baek J, McCartney A, Labbé C, Smith E, Chan SWS, Chen R, Brown C, Patel D, Liang M, Eng L, Sacher A, Bradbury P, Leighl NB, Shepherd FA, Xu W, Liu G, Hurry M, O'Kane GM
Oncotarget. 2019 Apr 26;10(31):2947-2958
Jiang DM, Fyles A, Nguyen LT, Neel BG, Sacher A, Rottapel R, Wang BX, Ohashi PS, Sridhar SS
Lung Cancer. 2019 May;131:86-89
O'Kane GM, Liu G, Stockley TL, Shabir M, Zhang T, Law JH, Le LW, Sacher A, Shepherd FA, Bradbury PA, Leighl NB
Clin Lung Cancer. 2018 Dec 22;:
Ezeife DA, Morganstein BJ, Lau S, Law JH, Le LW, Bredle J, Cella D, Doherty MK, Bradbury P, Liu G, Sacher A, Shepherd FA, Leighl NB
Methods Mol Biol. 2018;1768:193-207
Kuang Y, O'Connell A, Sacher AG, Feeney N, Alden RS, Oxnard GR, Paweletz CP
Cancer Cytopathol. 2017 Dec;125(12):896-907
Heymann JJ, Bulman WA, Swinarski D, Pagan CA, Crapanzano JP, Haghighi M, Fazlollahi L, Stoopler MB, Sonett JR, Sacher AG, Shu CA, Rizvi NA, Saqi A
Oncology (Williston Park). 2017 08 15;31(8):618-27
Komatsubara KM, Sacher AG
J Thorac Oncol. 2017 Sep;12(9):1344-1356
Sacher AG, Komatsubara KM, Oxnard GR
Eur J Radiol. 2017 Mar;88:15-20
Nishino M, Sacher AG, Gandhi L, Chen Z, Akbay E, Fedorov A, Westin CF, Hatabu H, Johnson BE, Hammerman P, Wong KK
Semin Oncol. 2016 Dec;43(6):638-646
Grigg C, Blake Z, Gartrell R, Sacher A, Taback B, Saenger Y


Staff Oncologist, Solid Tumor Oncology Program
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Assistant Professor of Medicine, University of Toronto